Yuanmei W. Zhu

Chinese Academy Of Medical Sciences And Peking Union Medical College
Beijing, 100730, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

The α-helix-facilitating amino acid sequence EAAAK dramatically increases the antiviral activity of SARS-CoV-2 fusion-inhibitory peptides via the endosome fusion pathway.

The α-helix-facilitating amino acid sequence EAAAK dramatically increases the antiviral activity of SARS-CoV-2 fusion-inhibitory peptides via the endosome fusion pathway.

Journal: Journal of virology

Published: September 08, 2026

Pharmacokinetics and safety of HIV fusion inhibitor Lipovirtide in non-human primates.

Pharmacokinetics and safety of HIV fusion inhibitor Lipovirtide in non-human primates.

Journal: Antiviral research

Published: November 04, 2025

Structural characterization of HIV fusion inhibitor LP-98: Insights into antiviral and resistance mechanisms.

Structural characterization of HIV fusion inhibitor LP-98: Insights into antiviral and resistance mechanisms.

Journal: Antiviral research

Published: April 08, 2025

Addition of a short HIV-1 fusion-inhibitory peptide to PRO 140 antibody dramatically increases its antiviral breadth and potency.

Addition of a short HIV-1 fusion-inhibitory peptide to PRO 140 antibody dramatically increases its antiviral breadth and potency.

Journal: Journal of virology

Published: March 25, 2025

An HIV fusion-inhibitory lipopeptide provides robust post-exposure prophylaxis and prevents viral reservoir seeding in macaques.

An HIV fusion-inhibitory lipopeptide provides robust post-exposure prophylaxis and prevents viral reservoir seeding in macaques.

Journal: Cell reports

Published: March 24, 2025

Pharmacokinetic and safety evaluation of lipopeptide-based HIV fusion inhibitor Lipovirtide in rats.

Pharmacokinetic and safety evaluation of lipopeptide-based HIV fusion inhibitor Lipovirtide in rats.

Journal: Antiviral research

Published: March 13, 2025

Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials.

Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials.

Journal: Antiviral research

Published: January 23, 2025

Development of lipopeptide-based HIV-1/2 fusion inhibitors targeting the gp41 pocket site with a new design strategy.

Development of lipopeptide-based HIV-1/2 fusion inhibitors targeting the gp41 pocket site with a new design strategy.

Journal: Antiviral research

Published: September 05, 2024

Prolonged release and antiviral efficacy of HIV fusion inhibitor LP-98-loaded microspheres in rhesus macaques.

Prolonged release and antiviral efficacy of HIV fusion inhibitor LP-98-loaded microspheres in rhesus macaques.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: June 19, 2024

Characterization of novel HIV fusion-inhibitory lipopeptides with the M-T hook structure.

Characterization of novel HIV fusion-inhibitory lipopeptides with the M-T hook structure.

Journal: Microbes and infection

Published: April 03, 2024

Diversity and phylogeny of yeasts in various habitats of the Arctic and Antarctic regions, with descriptions of one new family, five new genera and eighteen new species.

Diversity and phylogeny of yeasts in various habitats of the Arctic and Antarctic regions, with descriptions of one new family, five new genera and eighteen new species.

Journal: Persoonia

Published: March 05, 2024

Susceptibility and Resistance of SARS-CoV-2 Variants to LCB1 and Its Multivalent Derivatives.

Susceptibility and Resistance of SARS-CoV-2 Variants to LCB1 and Its Multivalent Derivatives.

Journal: Viruses

Published: October 26, 2023

Showing 1-12 of 47

Last Updated: 09/26/2026